Endoscopic Gastric Balloon Removal: It Ain’t Easy
Many congratulations to ReShape Medical for conducting the first obesity medical device trial in the United States that successfully met its endpoints. The results of the study were published recently in Surgery of Obesity and Related Diseases. One of the many differences between ElipseTM and endoscopic gastric balloons like the ReShape Duo ® is that ElipseTM is procedureless: no endoscopy or anesthesia is required. Here is why that is important. One patient in the ReShape study experienced a torn esophagus that led to bleeding while his ReShape balloon was being removed endoscopically. Another patient also experienced a torn esophagus and required intravenous antibiotics as a…
Allurion Technologies: A Treatment for Obesity That’s Easy to Swallow
Allurion Technologies and the Elipse Balloon were featured in the March issue of Medtech Strategist in an article entitled “Allurion Technologies: A Treatment for Obesity That’s Easy to Swallow”. Thank you to Mary Stuart for a very thoughtful profile of our company and device.
Gastric Balloons: Balancing Risk and Reward
A review on gastric balloons co-authored by the Allurion team will be published in the June issue of Gastrointestinal Endoscopy. In this video, senior author Dr. Ram Chuttani discusses the paper’s key findings and their implications for gastric balloons.
Team Allurion at NON INVA 2015
Team Allurion attended and gave two talks at the recent NON INVA conference in Lyon, France. Allurion presented an update on the Elipse System and a recently published review on gastric balloons. We would like to thank the organizers for a wonderful conference!
Dr. Shantanu Gaur presents at SAGES 2015
Allurion Technologies co-founder and Chief Scientific Officer Dr. Shantanu Gaur presented an update on the Elipse Balloon at the 2015 Society for American Gastrointestinal and Endoscopic Surgeons (SAGES) surgeons. We would like to thank the organizers of SAGES for a wonderful conference!
Gastric Balloon Review
Allurion co-founders Drs. Shantanu Gaur and Samuel Levy and Senior Medical Advisor Dr. Ram Chuttani recently co-authored an article entitled Balancing Risk and Reward: A Critical Review of the Intragastric Balloon for Weight Loss now in press at Gastrointestinal Endoscopy. The goal of this review was to answer 3 questions: How much weight is lost in gastric balloon therapy and is weight loss time-dependent? After gastric balloon therapy ends, how much weight loss is maintained? If adverse events occur, when do they occur in the course of gastric balloon therapy? The review concludes that 80% of the weight lost during gastric balloon therapy…
Repeat Gastric Balloon Therapy
Gastric balloons are sometimes criticized for being short-term therapies that lead to rapid but temporary weight loss. A previous post explores a recent study that demonstrates similar long-term outcomes and weight maintenance whether weight is lost rapidly or gradually. However, in some instances, an individual may desire repeat gastric balloon therapy to either continue losing weight or assist in weight maintenance. Is this possible? Repeat gastric balloon therapy has been studied and demonstrated to be safe and effective. In two separate studies, Dr. Alfredo Genco and Dr. Gontrand Lopez-Nava report that individuals who receive two balloons with a 1 month balloon-free period lost significantly…
Elipse Gastric Balloon Featured in WebMD
Allurion’s Elipse was recently featured in WebMD’s Future of Health series in an article entitled “The Next Generation of Weight Loss.” Click here to see the story!
Allurion co-founders featured in LeadDoc
Allurion Technologies co-founders Shantanu Gaur and Samuel Levy were featured in the latest edition of Lead Doc – the online journal for emerging physician leaders. Click here to read their story!
Slow and Steady Doesn’t Win the Race: It’s a Tie
A recently published paper in Lancet Diabetes and Endocrinology challenges the widely held notion that gradual weight loss is associated with better long-term outcomes than rapid weight loss. Purcell and colleagues randomized 200 people to either a rapid (12 weeks) or gradual (36 weeks) weight loss program (Phase 1) and then followed those who lost at least 12.5% of their weight for over 3 years to assess long-term outcomes (Phase 2). They concluded the following: After nearly 3 years of follow-up, people in both groups maintained ~30% of the weight they had lost (see figure) 81% of people in the rapid…